/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that focuses on discovering, developing, and commercializing small-molecule drugs targeting serious diseases. With a market cap of $128 billion, Vertex Pharmaceuticals’ operations span the Americas, Europe, Asia Pacific, the Middle East, and internationally.
Companies worth $10 billion or more are generally described as "large-cap stocks," and Vertex Pharmaceuticals fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the biotech industry. The company provides various products, including Trikafta, Symdeko/Symkevi, Orkambi, and Kalydeco, to treat cystic fibrosis.
